Article

Use adult RA assessment tools for juvenile idiopathic arthritis?

Continuous measures of disease activity used for assessment of adult rheumatoid arthritis may be valid measures in children with polyarticular-course juvenile idiopathic arthritis (JIA). The scores may be valid in larger cohorts of children with polyarticular-course JIA that include children with early JIA and with varying degrees of disease severity.

Continuous measures of disease activity used for assessment of adult rheumatoid arthritis may be valid measures in children with polyarticular-course juvenile idiopathic arthritis (JIA). The scores may be valid in larger cohorts of children with polyarticular-course JIA that include children with early JIA and with varying degrees of disease severity.

Ringold and colleagues performed a secondary analysis of data from 2 clinical trials to determine whether the Disease Activity Score (DAS), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) could be useful for polyarticular JIA. Disease activity was measured before and after treatment with etanercept in 94 patients with JIA; the results were compared with those measured with the American College of Rheumatology (ACR) Pediatric 30 criteria for improvement.

Moderate to very good correlation was found between continuous outcome measures-the DAS, DAS28, CDAI, and SDAI-and each set of ACR pediatric criteria. Values started high at baseline and declined to low levels by 6 months after treatment.

The authors noted that a continuous measure of disease activity in JIA would be a valuable tool that facilitates comparison of patient disease status and treatment response across clinical trials and their translation to clinical care.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.